Novo Nordisk and Eli Lilly $LLY stock slipped Thursday after Swiss pharma giant Roche posted positive results for its experimental weight loss pill CT-996. Sales of Johnson and Johnson’s blockbuster cancer drug Darzalex soared 18% year over year to $2.87 billion in the second quarter, helping the pharma giant outperform Wall Street expectations. And according to a new industry report by the investment bank William Blair, millennials and GLP-1 drug user are boosting sales of high-protein food and beverage products.
Check out those stories and more pharmaceutical news highlights from this week.
1 / 5
Shares of Novo Nordisk and Eli Lilly $LLY took a hit after Swiss pharma giant Roche posted positive results for its experimental weight loss pill.
2 / 5
Surging sales of Johnson & Johnson $JNJ’s blockbuster cancer drug Darzalex offset declining sales of some of the pharma giant’s other drugs, helping the company beat Wall Street expectations.
3 / 5
The next big thing in weight loss drugs isn’t weight loss. Wall Street Journal pharma reporter Peter Loftus made the case on Monday that the next wave of GLP-1 drug sales will be driven by the discovery of new medical uses for these slimming treatments.
4 / 5
Millennials and people on GLP-1 weight loss drugs driving up sales of high-protein packaged food and beverage products, according to a new industry report by the investment bank William Blair.
5 / 5
People taking weight loss drugs like Wegovy and Zepbound should tell their doctors ahead of a scheduled surgery, the European Medicines Agency warned on Friday.
